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The NADPH oxidase NOX2 
mediates loss of parvalbumin 
interneurons in traumatic 
brain injury: human autoptic 
immunohistochemical evidence
Stefania Schiavone, Margherita Neri  , Luigia Trabace & Emanuela Turillazzi
Pharmacological interventions for traumatic brain injury (TBI) are limited. Together with parvalbumin 
(PV) loss, increased production of reactive oxygen species (ROS) by the NADPH oxidase NOX enzymes 
represents a key step in TBI. Here, we investigated the contribution of NOX2-derived oxidative stress 
to the loss of PV immunoreactivity associated to TBI, performing immunohistochemistry for NOX2, 
8-hydroxy-2′-deoxyguanosine (8OHdG) and PV on post mortem brain samples of subjects died following 
TBI, subjects died from spontaneous intracerebral hemorrhage (SICH) and controls (CTRL). We detected 
an increased NOX2 expression and 8OHdG immunoreactivity in subjects died from TBI with respect to 
CTRL and SICH. NOX2 increase was mainly observed in GABAergic PV-positive interneurons, with a 
minor presence in microglia. No significant differences in other NADPH oxidase isoforms (NOX1 and 
NOX4) were detected among experimental groups. NOX2-derived oxidative stress elevation appeared 
a specific TBI-induced phenomenon, as no alterations in the nitrosative pathway were detected. Our 
results suggest that NOX2-derived oxidative stress might play a crucial role in the  
TBI-induced loss of PV-positive interneurons.
Traumatic brain injury (TBI) represents a dramatic health problem, being one of the leading cause of disabil-
ity1 and mortality2. TBI is commonly and most basically defined as an alteration in brain functioning or the 
emergence of brain pathology caused by an external force3. In head injury, different pathophysiological mech-
anisms occur which are set in motion by the injury event and take time to evolve4. In fact, the pathophysiology 
of TBI is extremely complex and heterogenous. Traditionally, “primary” versus “secondary” damage has been 
distinguished. However, over the years, it has become increasingly clear that brain injury may be considered 
a process beginning with an impact rather than a single event that may be then followed by secondary com-
plications4. In this ongoing process, overlapping and interrelated phenomena are intertwined5 and, following 
the primary mechanical damage, different neurodetrimental processes (secondary, non-mechanical damage) 
representing the pathophysiological consequences started at the time of the initial injury, occur6. These can 
result in several neurodetrimental effects, such as reduced blood flow and oxygen metabolism, metabolic dereg-
ulation and reduction in oxidative metabolism, glutamate-induced excitotoxicity, mitochondrial dysfunction 
and accumulation of reactive oxygen species (ROS) with a global increase of oxidative stress7–11. This phenom-
enon, resulting from a disequilibrium between the functioning of ROS-generating systems and antioxidants, 
has been widely reported as one of the key contributors to the development of TBI damage12. Although mito-
chondria have been described as the main source of ROS13, several evidences have pointed out a crucial role 
of the NADPH oxidase NOX enzymes to generation of superoxide, the most commonly occurring cellular free 
radical14. This enzymatic family, composed of several NOX isoforms distributed in a large variety of cells and 
tissues, has been shown to crucially contribute to different physiological and pathological functions14. In particu-
lar, NOX2 enzyme is known to regulate specific physiological pathways in the central nervous system (CNS)15 
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and to be a key player in the pathogenesis of CNS disorders, going from neurodegenerative16, 17 to psychiatric 
diseases18, 19. Recent reports described a key role of NADPH oxidase elevations in experimental rodent models 
of TBI, such as the “moderately severe weight-drop impact head injury” mouse model20, also supported by the 
beneficial effects of pharmacological or genetic NOX enzyme inhibition on TBI-induced neuronal damage21, 22. 
In particular, it has been demonstrated that intraperitoneal apocynin administration to rats before TBI was able to 
decrease ROS production, as well as prevent blood brain barrier disruption and microglia activation22. Moreover, 
apocynin treatment, immediately after TBI, determined a reduction of inflammatory and oxidative damage, with-
out any protective effect on the development of brain edema23. TBI-induced increase in the levels of malondial-
dehyde was also prevented by apocynin pretreatment20. Dysfunctions of GABAergic neurotransmission, another 
important pathological pathway leading to neuronal impairment following TBI, mainly occur through damage 
to parvalbumin (PV)-immunoreactive interneurons, in terms of loss and altered activity of this neuronal sub-
type24. However, the leading cause of decreased PV-positive neurons in TBI has not been clarified yet. Here, we 
investigated the possible contribution of the NADPH oxidase NOX2-derived oxidative stress to the loss of PV 
immunoreactivity in human subjects died following TBI compared to subjects died from spontaneous intracer-
ebral hemorrhage (SICH) and controls (CTRL). Post mortem brain samples of these subjects were analyzed for 
expression of NOX2, 8OHdG, PV and markers of nitrosative stress by immunohistochemistry. NOX2 expres-
sion in cellular brain subpopulations, i.e. neurons, in particular PV-immunoreactive interneurons, microglia and 
astrocytes was also evaluated.
Results
Increase of NOX2 and 8OHdG immunostaining in the cortex of subjects died following TBI. In 
order to investigate whether NOX2-derived oxidative stress might be involved in TBI-induced neuropathological 
alterations, we performed immunohistochemical analysis for NOX2 expression in the cortex of subjects died 
following TBI, compared to subjects died from SICH and CTRL. While NOX2 immunoreactivity was detected 
in very few cells of the frontal cortex of SICH subjects and CTRL, a significant elevation of the number of NOX2 
positive cells was observed in subjects died following TBI (Fig. 1A–D, One-way ANOVA, followed by Tukey’s 
post hoc test, F = 14.36; **P < 0.01; ***P < 0.001; n.s. = not significant). The same results were found for 8OHdG 
immunoreactivity evaluation (Fig. 1E–H, One-way ANOVA, followed by Tukey’s post hoc test, F = 17,72; 
***P < 0.001; n.s. = not significant). Moreover, in our experimental conditions, the observed increased NOX2 
expression in the frontal cortex of TBI subjects appears to be specific with respect to other NADPH oxidase 
isoforms, such as NOX1 and NOX4. Indeed, immunohistochemical analysis and pertaining quantifications 
showed the presence of a weak basal NOX1 staining in CTRL which did not significantly differ from the staining 
detected in TBI and SICH subjects (Suppl. Fig. 2A–C and G; One-way ANOVA, followed by Tukey’s post hoc 
test, F = 0,008367; P = 0,8332). The same was observed for NOX4 expression (Suppl. Fig. 2D–F and H One-way 
ANOVA, followed by Tukey’s post hoc test, F = 0,4614; P = 0,6364).
TBI-induced oxidative stress increase was associated to cortical PV-positive interneu-
rons decrease. In order to evaluate if TBI-induced increase in NOX2 expression might be associated to 
decreased number of cortical PV-positive interneurons, we performed immunohistochemical analysis for 
PV-immunoreactivity in the cortex of subjects died following TBI, compared to subjects died following SICH 
and CTRL. No differences were detected in the number of PV-positive cells between subjects died following SICH 
and CTRL, while a marked decrease of this protein immunoreactivity was observed in subjects died from TBI 
(Fig. 1I–L, One-way ANOVA, followed by Tukey’s post hoc test, F = 18,20; ***P < 0.001; n.s. = not significant).
NOX2 immunostaining was increased in the cortical GABAergic PV-positive interneurons of 
subjects died following TBI. To investigate which brain cellular subpopulation was involved in NOX2 ele-
vation, we performed double immunohistochemistry for NOX2, Neun, and GFAP. NOX2 and MAC387 were also 
investigated. NOX2 immunoreactivity was mainly found in Neun-positive cells (Fig. 2A), whereas virtually no 
NOX2 co-staining was detected in GFAP positive cells (Fig. 2B). The presence of co-stained NOX2/MAC387 cells 
indicated that microglia was also involved in the observed NOX2 elevation (Fig. 2C). To identify the neuronal 
subtype specifically implicated in NOX2 increase, double immunohistochemistry for NOX2 and DT1, NOX2 
and VGLUT1, NOX2 and GAD67, as well as NOX2 and PV was performed. While a weak NOX2 co-staining was 
detected in DT1 and VGLUT1 immunoreactive cells (Fig. 3A,B), a marked co-expression of NOX2 and GAD67 
was observed in the cortex of subjects died following TBI (Fig. 3C). Importantly, NOX2 immunoreactivity was 
detected in the PV-positive subtype of GABAergic neurons (Fig. 3D).
Nitrosative stress was not affected by TBI. In order to investigate if TBI specifically increased 
NOX2-derived oxidative stress or determined a non-specific elevation of oxidative and nitrosative pathways, we 
performed immunohistochemical analysis for iNOS and nitrotyrosine (NT), in the cortex of subjects died follow-
ing TBI, SICH and CTRL. Virtually no iNOS-positive cells were counted in the three groups (Fig. 4A–C) and the 
same was observed for NT immunoreactivity (Fig. 4D–F).
Discussion
In this study, we investigated the possible contribution of NOX2-derived oxidative stress to neuropathological 
alterations associated to TBI, with a particular focus on the loss of PV-positive interneurons. We found that 
expression of NOX2 was significantly increased in the cortex of subjects died following TBI, with respect to sub-
jects died from SICH and CTRL. The same was observed for the expression of 8OHdG, one of the predominant 
form of ROS-induced oxidative damage to DNA25, which has therefore been widely used as a very reliable bio-
marker for oxidative stress presence and previously found increased in preclinical and clinical investigations on 
central and peripheral neurological disorders as well as psychiatric illnesses26–31. Our results are in line with recent 
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findings reporting increased oxidative stress after TBI32, 33. Indeed, in a recent work, Lorente and co-workers 
demonstrated that total antioxidant capacity and lipid peroxidation state were strictly related to the mortality rate 
in TBI34. Consistent with these findings, other markers of oxidative stress such as thiobarbituric acid-reactive sub-
stances, 4-hydroxy-2-nonenal, 4-hydroxy-2-hexenal and isoprostanes have been shown as significantly increased 
in human plasmatic samples derived from TBI subjects35, 36. Protein carbonylation, another important marker 
of oxidative stress, has been also reported in a mouse model of TBI37. In this context, Harmon and co-workers 
recently demonstrated that TBI leads to mitochondrial disruption, in terms of induction of specific microRNA 
(miR-21 and miR-155), with consequent increased ROS production in the striatum of a rodent model of head 
injury38. Furthermore, current literature regarding the use of antioxidant therapies in treating TBI, including 
dexanabinol, amino acids, vitamins C and E, progesterone, N-acetylcysteine and enzogenol highlights the efficacy 
of these treatments in attenuating the oxidative stress induced by TBI39, 40. Interestingly, a report by Yilmaz and 
collaborators describes the beneficial effects of mannitol and hypertonic saline therapy in reducing TBI cellular 
damage by increasing levels of antioxidant enzymes such as catalase and glutathione peroxidase41.
Figure 1. Increase of oxidative stress and loss of PV-positive interneurons in the cortex of subjects died 
following traumatic brain injury. (A–C) Representative images of NOX2 immunostaining in the cortex 
of controls (CTRL, n = 5) (A), subjects died following TBI (TBI, n = 15) (B) and subjects died following 
spontaneous intracerebral hemorrhage (SICH, n = 5) (C). (D) Quantification of NOX2-positive-stained cells 
in the cortex of controls (CTRL, n = 5), subjects died following TBI (TBI, n = 15) and subjects died following 
spontaneous intracerebral hemorrhage (SICH, n = 5). Results are expressed as means ± s.e.m. One-way 
ANOVA, followed by Tukey’s post hoc test, F = 14.36; **P < 0.01; ***P < 0.001; n.s. = not significant. (E–G) 
Representative images of 8OHdG immunostaining in the cortex of controls (CTRL, n = 5) (E), subjects died 
following TBI (TBI, n = 15) (F) and subjects died following spontaneous intracerebral hemorrhage (SICH, 
n = 5) (G). (H) Quantification of 8OHdG-positive-stained cells in the cortex of controls (CTRL, n = 5), 
subjects died following TBI (TBI, n = 15) and subjects died following spontaneous intracerebral hemorrhage 
(SICH, n = 5). Results are expressed as means ± s.e.m. One-way ANOVA, followed by Tukey’s post hoc test, 
F = 17,72; ***P < 0.001; n.s. = not significant. (I–K) Representative images of PV immunostaining in the 
cortex of controls (CTRL, n = 5) (I), subjects died following TBI (TBI, n = 15) (J) and subjects died following 
spontaneous intracerebral hemorrhage (SICH, n = 5) (K). (L) Quantification of PV-positive-stained cells in 
the cortex of controls (CTRL, n = 5), subjects died following TBI (TBI, n = 15) and subjects died following 
spontaneous intracerebral hemorrhage (SICH, n = 5). Results are expressed as means ± s.e.m. One-way 
ANOVA, followed by Tukey’s post hoc test, F = 18,20; ***P < 0.001; n.s. = not significant.
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To the best of our knowledge, this is the first report evaluating NOX2 expression in human subjects died 
following severe TBI. Indeed, although several studies on rodents described an involvement of the NADPH oxi-
dase in TBI development42, as well as the beneficial effects of treatment with apocynin, an antioxidant/NOX 
inhibitor compound, or of NOX2 deficiency on TBI-induced neuronal damage20, 43, only one report described 
NOX2 and NOX4 increase in neurosurgical brain tissue samples derived from alive human subjects, correlat-
ing negatively both NOX2 and NOX4 positive immunoreactivity with the Glasgow Coma Scale of these sub-
jects44. We also demonstrated that, together with increased NOX2 expression and oxidative stress, cortical 
PV-immunoreactivity was reduced in subjects died following TBI. Recent findings highlight the crucial role of 
dysfunctions of PV-positive interneurons, in terms of both loss and impaired activity, in the development of brain 
damage induced by traumatic injury45, 46. However, these studies have been mainly realized on rodent models 
of TBI. The observed decrease in PV-immunoreactivity is in line with a paper of Buriticá and co-workers per-
formed on human cortical contusion tissue, describing changes in PV-positive interneurons amount in layer 
II47. In the present study, we showed that NOX2 elevation mainly occurs in neurons with a minor presence of 
NOX2 immunoreactivity in microglial cells. Our results are in line with previous observations obtained on 
mice, reporting that, following TBI, the NADPH oxidase expression and activity exhibit a biphasic elevation 
in the cerebral cortex and hippocampus, with an early peak of increase in neurons, followed by a second phase 
in which NOX2 expression is also detectable in microglial cells21. In the same line, Cooney et al. reported that 
increased NOX2 expression occurs in neurons and microglia and that inhibition of NOX, and more specifically 
NOX2, might decrease pro-inflammatory activity in microglia48. ROS production by NADPH oxidase, as well as 
the number of degenerating neurons in the hippocampal CA3 region and microglial activation after TBI, were 
also inhibited by apocynin administration22. In support of this, Kumar and collaborators recently showed, in 
an experimental model of TBI, that NOX2 is highly up-regulated in infiltrating macrophages after injury and 
that NOX2 deficiency reduces the expression of markers of microglia activation, limiting brain tissue degener-
ation and improving motor recovery49. Importantly, here, we showed an increased NOX2 immunoreactivity in 
GABAergic neurons and, in particular, in PV-positive interneurons. This is a crucial finding of this study, allow-
ing us to hypothesize a possible molecular mechanism linking neuronal injury, NOX2-derived oxidative stress 
increase and TBI-induced dysfunctions of GABAergic and glutamatergic neurotransmission. Indeed, TBI might 
Figure 2. NOX2 increase in cortical neurons and microglia of subjects died following TBI. (A–C) 
Representative contrast phase images of double immunostaining for NOX2/Neun (A), NOX2/GFAP (B) and 
NOX2/MAC387 (C) in the cortex of subjects died following TBI (n = 15).
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induce an increase of NOX2 expression in GABAergic PV-positive interneurons with consequent ROS produc-
tion elevation in this cortical cellular subtype and oxidative damage, causing neuronal death. The decrease in 
GABAergic PV-positive interneurons is responsible for the loss of the inhibitory tone, leading to excessive gluta-
mate release and consequent excitoxicity-induced neuronal death. Increased NOX2 expression in microglial cells 
might enhance ROS amount that can further damage the PV-positive interneurons, contributing to their degen-
eration and loss (Fig. 5). This hypothesized molecular mechanism is supported by previous preclinical findings 
on the ketamine model of psychosis reporting a similar mechanism linking the loss of phenotype of fast-spiking 
Figure 3. NOX2 increase in cortical GABAergic PV-positive interneurons. (A–D) Representative contrast 
phase images of double immunostaining for NOX2/DT1 (A), NOX2/VGLUT1 (B), NOX2/GAD67 (C) and 
NOX2/PV (D) in the cortex of subjects died following TBI (n = 15).
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PV-positive interneurons, NADPH oxidase increase and dysfunctions of GABAergic and glutamatergic neuro-
transmission50, 51. Moreover, recent reports on human post mortem brain samples of suicidal subjects as well as 
of a cocaine abuser died following excited delirium syndrome identify GABAergic neurons as the most impli-
cated in the increase of NOX2-derived ROS production26, 27. Interestingly, at least in our samples, we detected 
no differences in iNOS and NT immunoreactivity among the different groups, therefore suggesting a specific 
effect of TBI on oxidative but not nitrosative stress. Contrasting results regarding the effects of TBI-induced 
nitric oxide (NO) production have been reported52. Indeed, some studies on rodents showed an enhancement of 
the nitrergic system after TBI and a decrease of neuronal necrosis after aminoguanidine administration53, 54. In 
contrast, recent consistent findings point towards a protective role of the nitrergic pathways against TBI-induced 
neuronal damage. In this line, prolonged aminoguanidine treatment have been demonstrated to exacerbate brain 
injury in rats. Furthermore, brain injured iNOS knock-out mice showed worse functional outcome than wild 
type mice55. Rangel-Castilla and co-workers described a two-step model of NO metabolism after TBI, including 
a phase of immediate increase in NO levels after TBI, followed by a later period of decrease56. Beyond a possible 
neuroprotective effect, the absence of concomitant nitrergic pathway alterations observed in our study is also 
supported by a very recent study reporting a pathogenetic association between TBI-induced increase of NO 
levels and impairment of mitochondrial respiratory chain57. Another crucial finding of the present work is the 
absence of NOX2-derived oxidative stress increase in subjects died following SICH, indicating that TBI effects 
on NADPH oxidase are not non-specific findings. This result might be considered in apparent contradiction with 
previous findings on rodents reporting an association between intracerebral hemorrhage-induced brain injury 
and enhanced expression of the gp91phox subunit of the NADPH oxidase58. However, beyond the impossibility 
Figure 4. The nitrergic system is not affected by TBI. (A–C) Representative images of iNOS immunostaining 
in the cortex of controls (CTRL, n = 5) (A), subjects died following TBI (TBI, n = 15) (B) and subjects died 
following spontaneous intracerebral hemorrhage (SICH, n = 5) (C). (D–F) Representative images of NT 
immunostaining in the cortex of controls (CTRL, n = 5) (D), subjects died following TBI (TBI, n = 15) (E) and 
subjects died following spontaneous intracerebral hemorrhage (SICH, n = 5) (F).
Figure 5. Hypothetical molecular mechanism linking NOX2-derived oxidative stress increase and TBI-induced 
dysfunctions of GABAergic and glutamatergic neurotransmission. TBI might cause an increase of NOX2 
expression in GABAergic PV-positive interneurons with consequent oxidative damage-induced neuronal death. 
The decrease in GABAergic PV-determines the loss of the inhibitory tone, leading to excitoxicity. In addition, 
increased NOX2 expression in microglial cells might enhance ROS amount, further damaging PV-positive 
interneurons.
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of a direct translation of a study on rodents to human investigations, this previous work was performed on mice 
at 20-35 weeks of age, therefore mimicking an older patient population, while the subjects died following SICH 
included in our study did not cover this age range. Moreover, in support of our observations, neuronal injury 
induced by SICH has been related to mitochondrial dysfunctions59, 60. A limitation of the present study is repre-
sented by the lack of a direct NOX activity measurement in these human brain samples. With respect to this miss-
ing aspect, although it represents certainly a crucial step in the understanding of physiological and pathological 
roles of the NADPH oxidase, no efficient and reliable methods to directly measure NOX activity in the brain are 
actually available61.
In conclusion, our study performed on human post mortem brain samples suggests a crucial and specific role 
of NOX2 enzyme in the development of early neuropathological alterations induced by TBI, and may represent a 
significant progress in the understanding of the multiple cellular and subcellular mechanisms occurring in severe 
TBI62. An important goal common both to clinicians and pathologists is to highlight the cascade of molecular 
pathways involved in the onset and progression of TBI injury with the aim of developing more targeted and spe-
cific pharmacologic interventions to improve the outcomes of TBI. Hence, although many existing preclinical 
studies have tested the therapeutic efficacy of several compounds in animal models by targeting specific pathways 
leading to neuronal injury (including calcium channel blockers, corticosteroids, excitatory amino acid inhibi-
tors, NMDA receptor antagonists and free radical scavengers63), all these pharmacological approaches did not 
hit the target64 and did not show satisfactory clinical success so far, probably because of their focusing on single 
events, rather than taking the heterogeneous TBI pathology into account65. In this context, the identification of 
the NADPH oxidase NOX2 as crucial and specific molecular agent leading to TBI-associated neuropathological 
alterations, such as the loss of PV interneurons, might open the way to several significant clinical implications 
such as a possible and attractive therapeutic use of selective NOX2 inhibitor compounds in TBI and/or the early 
identification of patients with a worst follow-up or prognosis. Indeed, the significant contribution of NOX2 to 
TBI-associated neuropathology might be considered as a reliable biomarker to be also used in clinics for the iden-
tification of individual differences in the pharmacological response. Further research in this area is clearly needed, 
especially regarding the possibility to directly measure ROS production (superoxide and/or H2O2) by NOX2 
enzyme in biological samples and unfixed brain tissue of TBI subjects or to investigate possible treatment-related 
NOX2 expression changes. A time-course analysis of NOX2 expression in subgroups of patients, at different time 
points from TBI, would be also an important future direction for works in this area.
Methods
Case selection. Cases were selected from the case series of the section of Legal Medicine, Department of 
Clinical and Experimental Medicine, University of Foggia, Italy. A total of 15 patients with severe TBI were stud-
ied (men and women). The mean age was 38 ± 15 years. The mechanism of injury was blunt injury, with 12 motor 
vehicle accidents (including pedestrians or bicyclists hit by car), 2 falls, and 1 accident at work. After trauma, all 
subjects were admitted to the intensive care and underwent initial stabilization in the emergency room. When 
indicated, craniotomies were performed for evacuation of intracranial hematomas. The main inclusion criteria 
were a Glasgow Coma Scale (GCS) score ≤ 8 following initial resuscitation and the occurrence of an increase in 
neurological deficit or a deepening of the level of consciousness until death. The main exclusion criteria were 
history of previous neurologic disease or TBI and of recreational abuse of psychoactive compounds. Abusive 
head trauma was also excluded. Toxicological analyses for the most common drugs of abuse (cocaine, heroin, 
amphetamine, methadone and cannabinoids) were negative for all subjects included in the study. As CTRL, we 
selected subjects died from sudden cardiac death (n = 5). As second control group, we included subjects died 
from SICH (n = 5).
Technical details. For all subjects included in the study, autopsy was performed between 24 and 72 h after 
death. To avoid the progression of transformative phenomena, bodies were kept in cold storage room (−5 °C) 
until autopsy. Standard sample blocks were taken from the area of focal damage (if macroscopically visible), the 
cerebral cortex, white and grey matters, basal ganglia, thalami, callosum and the brainstem. In each case, the tis-
sue samples were fixed in 10% formalin for 48 h and then processed and embedded in paraffin.
Histological and immunohistochemical study. For each case, total sections of about 4 µm thickness 
were cut and stained with haematoxylin and eosin (H&E). Immunohistochemical investigation was performed as 
previously described26, 27, using antibodies against one or a combination of the following markers: NOX2 (1:50, 
Santa Cruz, California), 8OHdG (1:10, JaICA, Japan), Neun (1:1000, Abcam, Cambridge, United Kingdom), 
MAC387 (1:200, Santa Cruz, California), GFAP (1:300, Santa Cruz, California), GAD67 (1:2000, Abcam, United 
Kingdom), VGLUT1 (1:500, Abcam, United Kingdom), DT1 (1:100 Abcam, United Kingdom), nitrotyrosine 
(NT, 1:600, Santa Cruz, California), iNOS (1:100,Santa Cruz, California), parvalbumin (1:2000 Abcam, United 
Kingdom), NOX1 (1: 250 Abcam United Kingdom) and NOX4 (1:100 Abcam United Kingdom). iNOS and 
NOX2 specificity was tested on positive and technical negative controls (Suppl. Fig. 1). To identify the cellu-
lar subtype involved in NOX2 increase, double immunohistochemistry was performed using several peroxidase 
substrates with different colors: Vector NovaRED (red), Vector VIP (purple), Vector SG (blue/grey) and DAB 
(brown; Vector, Burlingame, CA, USA). A summary of the markers studied with immunohistochemical reaction 
is provided in Table 1.
Sections were counterstained with methyl green, dehydrated, coverslipped and observed in a Leica DM6000 
optical microscope (Leica, Cambridge, UK). Quantification of NOX2, 8OHdG, PV, iNOS and NT positive stained 
cells was performed using the ImageJ software (imagej.nih.gov/ij/) and expressed as number of positive stained 
cells/analysed area.
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Statistical analysis. Data were analysed using the GraphPad Prism 5 software for Windows (La Jolla, CA, 
USA). Data were checked for normality by Bartlett test and analyzed by One-way analysis of variance (ANOVA), 
followed by Tukey’s post hoc test. For all tests, a P value < 0.05 was considered statistically significant.
Data availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request.
Compliance with Ethical Standards. This study was performed by using human post mortem brain sam-
ples, collected during autopsies ordered by the prosecutor and used after the end of the investigations. According 
to the Italian law, no authorizations from the ethics committee regarding the use of these post mortem brain 
samples were required.
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NOX2 NADPH oxidase 2 or Nox2 is a protein that in humans is encoded by the CYBB gene. The protein is a superoxide generating enzyme which forms reactive oxygen species (ROS).
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